1-160130283-G-A
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM2PM5PP2PP3_StrongPP5_Very_Strong
The ENST00000361216.8(ATP1A2):c.1643G>A(p.Arg548His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000205 in 1,461,882 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R548C) has been classified as Pathogenic.
Frequency
Consequence
ENST00000361216.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATP1A2 | NM_000702.4 | c.1643G>A | p.Arg548His | missense_variant | 12/23 | ENST00000361216.8 | NP_000693.1 | |
ATP1A2 | XM_047421286.1 | c.752G>A | p.Arg251His | missense_variant | 5/16 | XP_047277242.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATP1A2 | ENST00000361216.8 | c.1643G>A | p.Arg548His | missense_variant | 12/23 | 1 | NM_000702.4 | ENSP00000354490 | P1 | |
ATP1A2 | ENST00000392233.7 | c.1643G>A | p.Arg548His | missense_variant | 12/23 | 5 | ENSP00000376066 | |||
ATP1A2 | ENST00000447527.1 | c.776G>A | p.Arg259His | missense_variant | 5/16 | 2 | ENSP00000411705 | |||
ATP1A2 | ENST00000472488.5 | n.1746G>A | non_coding_transcript_exon_variant | 12/20 | 2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251212Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135836
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461882Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 727244
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Migraine, familial basilar Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 13, 2005 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 25, 2020 | Published in vitro functional studies demonstrated that R548H variant results in reduced ATPase activity, alters the affinity for sodium and potassium, and reduces catalytic turnover compared to the wild type protein (Swarts et al., 2013); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 18498390, 23954377, 16088919, 16344534, 27445835) - |
ATP1A2-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | - | This variant has been previously reported as a heterozygous change in patients with Hemiplegic migraine and Basilar migraine (PMID: 16344534, and Maksemous et al., 2019). Additionally, a different variant at the same amino acid position (p.Arg548Cys) has been seen in multiple patients with ATP1A2-Related Disorders (ClinVar Variation ID: 871961). In vitro overexpression studies revealed that the c.1643G>A (p.Arg548His) variant has reduced Na(+) affinity and increased K(+) affinity, leading to reduced catalytic turnover compared to the wild type protein (PMID: 23954377). It is present in the heterozygous state in the gnomAD population database at a frequency of 0.0004% (1/251212) and thus is presumed to be rare. The c.1643G>A (p.Arg548His) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.1643G>A (p.Arg548His) variant is classified as Pathogenic. - |
Migraine, familial hemiplegic, 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jul 18, 2024 | Criteria applied: PS4_MOD,PM2,PM5,PS3_SUP,PP1,PP2,PP3 - |
Familial hemiplegic migraine Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 12, 2023 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg548 amino acid residue in ATP1A2. Other variant(s) that disrupt this residue have been observed in individuals with ATP1A2-related conditions (PMID: 18498390), which suggests that this may be a clinically significant amino acid residue. Experimental studies have shown that this missense change affects ATP1A2 function (PMID: 23954377). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ATP1A2 protein function. ClinVar contains an entry for this variant (Variation ID: 12926). This missense change has been observed in individuals with clinical features of autosomal dominant ATP1A2-related conditions (PMID: 16344534; Invitae; Maksemous et al. 2019 Cephalagia Reports Vol. 2). This variant is present in population databases (rs121918616, gnomAD 0.0009%). This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 548 of the ATP1A2 protein (p.Arg548His). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at